Traditional oncology drug development has relied on identifying the maximum tolerated dose. A new study shows that this approach may not be required for molecules like FAP-4-1BBL. Read the full study via ASCPT Journal Family: ➡ https://bit.ly/3ukqkNg | #PrecisionMedicine #ModelInformedPrecisionDosing #PrecisionDosing
